| May 28 |
Insmed stock blasts off over lung condition study results
|
| May 28 |
Insmed Strikes Gold With Phase 3 Bronchiectasis Win (Rating Upgrade)
|
| May 28 |
The Next Humira? Insmed Catapults 113% On Its 'Very Attractive' Opportunity In Lung Disease.
|
| May 28 |
Why Is Inflammatory Diseased-Focused Insmed Stock Soaring On Tuesday?
|
| May 28 |
Stocks to Watch Tuesday: GameStop, Apple, Nvidia, Hess
|
| May 28 |
Insmed Shares Rocket After Drug Eases Lung Disease Symptoms
|
| May 28 |
Insmed Stock More Than Doubles on Trial Win for Lung-Condition Drug
|
| May 28 |
Insmed shares double as lung drug data convince Wall Street
|
| May 28 |
Insmed surges on late-stage win for lung disease therapy
|
| May 28 |
Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis
|
